Interleukin 3 in the treatment of chemotherapy induced thrombocytopenia

Oncology Reports

Volumn 5, Issue 6, 1998, Pages 1459-1464

  Leonardi, V ^a   Danova, M ^b   Fincato, G ^c   Palmeri, S ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b AZIENDA Socio Sanitaria Territoriale di Pavia   (Italy)

^c Mediolanum Farmaceutici   (Italy)

Author keywords

Chemotherapy induced thrombocytopenia; Colony stimulating factor; Interleukin 3; Myelosuppression

Indexed keywords

ANTHRACYCLINE; ANTIINFECTIVE AGENT; CYCLOPHOSPHAMIDE; DACARBAZINE; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; INTERLEUKIN 3; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PLATINUM DERIVATIVE; VINCA ALKALOID;

ADULT; AGED; ALLERGY; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; NEUROTOXICITY; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031667679     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.6.1459     Document Type: Article

References (35)

1. Chevallier B, Chollet P, Merrouche Y, et al: Lenogastrim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 13: 1564-1571, 1995.
2. Bodey GP, Bucley M, Sathe YS, et al: Quantitative relationship between circulating leucocytes and infection in patients with acute leukemia. Ann Intern Med 64: 328-340, 1996.
3. Hryniuk WK: Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14: 65-73, 1987.
4. Pizzo PA, Hathorn JW, Hiemenz J, et al: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315: 552-558, 1986.
5. Postmus PE, Gieterna JA, Biesma B, et al: Effect of recombinant human interleukin 3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose finding study. J Clin Oncol 10: 1131-1140, 1992.
6. Gabrilove JL, Jakubowsky A, Scer H, et al: Effects of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of urothelium. N Engl J Med 318: 1414-1422, 1988.
7. Crawford J, Ozer H, Stoller D, et al: Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 325: 164-170, 1991.
8. Antmans KS, Griffin JD, Elias A, et al: Effects of recombinant human granulocyte colony stimulating factors on chemotherapy induced myelosuppression. N Engl J Med 319: 593-598, 1988.
9. Edmonson JH, Long HJ, Jeffries JA, et al: Amelioration of chemotherapy induced thrombocytopenia by GM-CSF: apparent dose and schedule dependency. J Natl Cancer Inst 81: 1510-1512, 1989.
10. De Vries EGE, Biemsa B, Willemse PHB, et al: A double blind placebo controlled study with granulocyte macrophage colony stimulating factors during chemotherapy for ovarian carcinoma. Cancer Res 51: 116-122, 1991.
11. Vose JM and Armitage JO: Clinical application of hematopoietic growth factors. J Clin Oncol 13: 1023-1035, 1995.
12. Brugger W, Frisch J, Pressler K, et al: Sequential administration of Interleukin 3 and granulocyte macrophage colony stimulating factors following standard dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. J Clin Oncol 10: 1452-1459, 1992.
13. Oster W: Interleukin 3: biological and clinical effect. Int J Cell Cloning 9: 5-23, 1991.
14. Hill ADK, Redmond HP, Croke DT, et al. Cytokines in tumor therapy. Br J Surg 79: 990-997, 1992.
15. Morris CF, Young IG and Hapel AJ: Molecular and cellular biology of Interleukin 3. Immunol Ser 49: 177-214, 1990.
16. Yang YC and Clark SC: Human Interleukin 3: analysis of the gene and its role in the regulation of hematopoiesis. Int J Cell Cloning 8: 121-128, 1990.
17. Yang YC and Clark SC: Interleukin 3: molecular biology and biologic activities. Hematol Oncol Clin North Am 3: 441-452, 1989.
18. Kindler V, Thorens B, De Kossodo S, et al: Stimulation of hematopoiesis in vivo by recombinant bacterial murine interleukin 3. Proc Natl Acad Sci USA 83: 1001-1005, 1986.
19. Metcalf D, Begley CG, Johnson GR, et al: Effect of purified bacterially synthetized murine multi CSF (IL3) on hematopoiesis in normal adult mice. Blood 68: 46-57, 1986.
20. Broxmeyer HE, Williams DE, Hangoc G, et al. Synergistic myelopoietic actions in vivo after administration to mice of combination of purified natural murine colony stimulating factors1, recombinant murine interleukin 3 and recombinant murine granulocyte/macrophage colony stimulating factors. Proc Natl Acad Sci USA 84: 3871-3875, 1987.
21. Donahue RE, Seehra J, Metzger M, et al: Human IL3 and GM CSF act synergistically in stimulating hematopoiesis in primates. Science 241: 1820-1823, 1988.
22. Biesma B, Willemse PHB, Mulder NH, et al: Effect of interleukin 3 after chemotherapy for advanced ovarian cancer. Blood 80: 1141-1148, 1992.
23. Gianella-Borradori A: Present and future clinical relevance of Interleukin 3. Stem Cells 12: 214-248, 1994.
24. Meyer M, Vehmeyer K, Liersch T, et al: Effects of continuous infusion of recombinant human interleukin 3 alone or in combination with GM-CSF on erythropoiesis after intensive chemotherapy. Cancer Res Clin Oncol 118 (Suppl.): 27, 1992.
25. Aglietta M, Pasquino P, Sanavio F, et al: Granulocyte-Macrophage colony stimulating factors and interleukin 3: target cell and kinetics of response in vivo. Stem Cells 11: 83-87, 1993.
26. Frendl G: Interleukin 3: from colony stimulating factor to pluripotent immunoregulatory cytokine. Int J Immunopharmacol 14: 21-30, 1992.
27. Ihle JN: Interleukin 3 and hematopoiesis. Chem Immunol 51: 65-106, 1992.
28. Sculz G, Krumwieh D and Oster W: Adjuvant therapy with recombinant interleukin 3 and granulocyte macrophage colony stimulating factor. Pharmacol Ther 51: 85-94, 1991.
29. Ganser A, Linderman A, Seipelt G, et al: Clinical effect of recombinant human interleukin 3. Am J Clin Oncol 14: 51-63, 1991.
30. Veldhuis GJ, Willemse PHB, van Gameran MM, et al: Recombinant human interleukin 3 to dose intensify carboplatin and cyclophospahmide chemotherapy in epitelial ovarian cancer: A phase I trial. J Clin Oncol 13: 733-740, 1995.
31. Dercksen MW, Hoekman K, Ten Bokkel Huinink WW, et al: Effect of interleukin 3 on rnyelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumors. J Cancer 68: 996-1003, 1993.
32. Matsumoto T: Ongoing IgE synthesis by atopic B cells is enhanced by interleukin 3 and suppressed directly by interferon gamma in vivo. Int Arch Allergy Appl Immunol 95: 48-52, 1991.
33. MacDonald SM, Schleimar RP, Kagey-Sobotka A, et al: Recombinat IL3 induces histamine release in human basophils. Immunology 142: 3527-3532, 1989.
34. Sugiyama H, Eda R, Hopp RJ, et al: Importance of interleukin 3 on histamine release from human basophils. Ann Allergy 71: 391-395, 1993.
35. Mayer P, Valent P, Schmidt G, et al: The in vivo effects of recombinant human interleukin 3: demonstration of basophil differentation factor, histamine-producing activity and priming of GM-CSF responsive progenitors in non-human primates. Blood 74: 613-621, 1989.